Curanex Pharmaceuticals (CURX) Q1 2026 earnings summary

Executive summary

• Focused on developing botanical drugs for inflammatory diseases, with Phyto-N as the lead candidate targeting ulcerative colitis and other indications.

• Advanced Phyto-N toward a planned Q4 2026 IND submission for ulcerative colitis, completing key manufacturing and toxicology milestones.

• Expanded pipeline to include cancer cachexia, a serious condition with no FDA-approved therapies, enhancing long-term growth potential.

• Completed IPO in August 2025, raising net proceeds of approximately $13.24 million, with an additional $2.07 million from over-allotment.

• No revenue generated in Q1 2026 as the company remains in the development stage.

Financial highlights

• Net loss for Q1 2026 was $3,150,228, compared to $137,583 in Q1 2025.

• General and administrative expenses rose to $927,197 from $137,452 year-over-year, mainly due to increased payroll and public company costs.

• Research and development expenses were $2,256,162, reflecting ongoing IND-enabling studies.

• Cash and cash equivalents totaled $4,018,574 as of March 31, 2026, up from $198,943 a year earlier.

Outlook and guidance

• Plans to submit an IND for Phyto-N in ulcerative colitis in Q4 2026, with Phase I trials to follow pending FDA approval.

• Near-term priorities include advancing GLP toxicology and pharmacokinetic studies, manufacturing, regulatory preparation, and evaluating pipeline expansion, notably cancer cachexia.

• R&D spending expected to remain significant as studies progress, but to moderate until clinical trials commence.

• Management believes current cash is sufficient to fund operations for at least the next twelve months.